Valneva SE
PAR:VLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Valneva SE
Accounts Receivables
Valneva SE
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Valneva SE
PAR:VLA
|
Accounts Receivables
€27.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Accounts Receivables
€40.3m
|
CAGR 3-Years
133%
|
CAGR 5-Years
120%
|
CAGR 10-Years
21%
|
|
|
Inventiva SA
PAR:IVA
|
Accounts Receivables
€10.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Accounts Receivables
$14.4m
|
CAGR 3-Years
165%
|
CAGR 5-Years
23%
|
CAGR 10-Years
8%
|
|
|
DBV Technologies SA
PAR:DBV
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Valneva SE
Glance View
Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
See Also
What is Valneva SE's Accounts Receivables?
Accounts Receivables
27.8m
EUR
Based on the financial report for Dec 31, 2025, Valneva SE's Accounts Receivables amounts to 27.8m EUR.
What is Valneva SE's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
6%
Over the last year, the Accounts Receivables growth was -21%. The average annual Accounts Receivables growth rates for Valneva SE have been 5% over the past three years , 8% over the past five years , and 6% over the past ten years .
